Intranasal delivery of zidovudine by PLA and PLA-PEG blend nanoparticles

International Journal of Pharmaceutics

Volumn 395, Issue 1-2, 2010, Pages 266-271

  Mainardes, Rubiana Mara ^a   Khalil, Najeh Maissar ^a   Gremião, Maria Palmira Daflon ^b  

^a UNIVERSIDADE ESTADUAL DO CENTRO OESTE   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Bioavailability; Intranasal administration; Nanoparticles; Zidovudine

Indexed keywords

MACROGOL; NANOPARTICLE; POLYLACTIDE; ZIDOVUDINE; DRUG CARRIER; LACTIC ACID; MACROGOL DERIVATIVE; POLYLACTIC ACID; POLYMER; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; BLOOD; CHEMISTRY; HALF LIFE TIME; INTRANASAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; MOUSE; PHARMACEUTICS; PROCEDURES; SURFACE PROPERTY; WISTAR RAT;

ADMINISTRATION, INTRANASAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; HALF-LIFE; LACTIC ACID; MALE; MICE; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYMERS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE INHIBITORS; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL; ZIDOVUDINE;

EID: 77954314547     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.05.020     Document Type: Article

References (43)

1. Aarnoutse R., Schapiro J.M., Bouchr C.A.B., Hkster Y.A., Burger D.M. Therapeutic drug monitoring. Drugs 2003, 63:741-753.
2. Allémann E., Gurny R., Doelker E. Drug loaded nanoparticles preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm. 1993, 39:173-191.
3. Alonso M.J. Nanomedicines for overcoming biological barriers. Biomed. Pharmacother. 2004, 58:168-172.
4. Aungst B.J. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Adv. Drug Deliv. Rev. 1999, 39:105-116.
5. Beletsi A., Palazi Z., Avgoustakis K. Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers. Int. J. Pharm. 2005, 298:233-241.
6. Blum M.R., Liao S.H.T., Good S.S., Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 1988, 85:189-194.
7. Brooking J., Davis S.S., Illum L. Transport of nanoparticles across the rat nasal mucosa. J. Drug Target. 2001, 9:267-279.
8. Carstensen H., Muller R.H., Muller B.W. Particle-size, surface hydrophobicity and interaction with serum of parenteral fat emulsions and model-drug carriers as parameters related to RES uptake. Clin. Nutr. 1992, 11:289-297.
9. Chien Y.W., Wearley L.L. AIDS and chemotherapy. Drugs Today 1989, 25:19-25.
10. Csajka C., Marzollini C., Fattinger K., Décosterd L.A., Telenti A., Biollaz J., Buclin T. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin. Pharm. Ther. 2003, 73:20-30.
11. Dong Y., Feng S.-S. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 2004, 25:2843-2849.
12. Fernández-Urrusuno R., Fattal E., Rodrigues J.M., Féger J., Bedossa P., Couvreur P. Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice. J. Biomed. Mater. Res. 1996, 31:401-408.
13. Furman P.A., Fufe J.A., St.Claire M.H., Weinhold K., Rideout J.L., Freeman G.A., Nusinhof-Lehrman S., Bolognesi D.P., Broder S., Mitsuya H., Barry D.W. Phosphorylation of 3%-azido-3%-deoxythymidine and selective interaction of the 5%-triphosphate with human immunodefiency virus reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 1986, 83:8333-8337.
14. Gill P.S., Rarick M., Brynes R.K., Causey D., Loureiro C., Levine A.M. Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS). Ann. Int. Med. 1987, 107:502-505.
15. Gref R., Domb A., Quellec P., Blunk T., Muller R.H., Verbavatz J.M., Langer R. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Deliv. Rev. 1995, 16:215-223.
16. Hoffart V., Lamprecht A., Maincent P., Lecompte T., Vigneron C., Ubrich N. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J. Control. Release 2006, 113:38-44.
17. Huang Y., Donovan M.D. Large molecule and particulate uptake in the nasal cavity: the effect of size on nasal absorption. Adv. Drug Deliv. Rev. 1998, 29:147-155.
18. Kennedy C.A., Griffith H.S., Mathison G.E. Erythrocytosis after zidovudine for AIDS. Ann. Int. Med. 1991, 114:250-251.
19. König H., Behr E., Löwer J., Kurth R. Azidothymidine triphosphate is an inhibitor of both human immunodeficiency virus type 1 reverse transcriptase and DNA polymerase gamma. Antimicrob. Agents Chemother. 1989, 33:2109-2114.
20. Li X.L., Chan W.K. Transport, metabolism and elimination mechanisms of anti-HIV agents. Adv. Drug Deliv. Rev. 1999, 39:81-103.
21. Mainardes R.M., Gremião M.P., Brunetti I.L., da Fonseca L.M., Khalil N.M. Zidovudine-loaded PLA and PLA-PEG blend nanoparticles: influence of polymer type on phagocytic uptake by polymorphonuclear cells. J. Pharm. Sci. 2009, 98:257-267.
22. Mainardes R.M., Gremião M.P.D. Reversed phase HPLC determination of zidovudine in rat plasma and its pharmacokinetics after a single intranasal dose administration. Biol. Res. 2009, 42:357-364.
23. Mainardes R.M., Urban M.C., Cinto P.O., Chaud M.V., Evangelista R.C., Gremião M.P. Liposomes and micro/nanoparticles as colloidal carriers for nasal drug delivery. Curr. Drug Deliv. 2006, 3:275-285.
24. Morimoto K., Kstsumata H., Yabuta T., Iwanaga K., Kakemi M., Tabata Y., Ikada Y. Evaluation of gelatin microspheres for nasal and intramuscular administrations of salmon calcitonin. Eur. J. Pharm. Sci. 2001, 13:179-185.
25. Nakada Y., Fattal E., Foulquier M., Couvreur P. Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice. Pharm. Res. 1996, 13:38-43.
26. Norman M.E., Williams P., Illum L. Human serum-albumin as a probe for surface conditioning (opsonization) of block copolymer-coated microspheres. Biomaterials 1992, 13:841-849.
27. Ojewole E., Mackraj I., Naidoo P., Govender T. Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur. J. Pharm. Biopharm. 2008, 70:697-710.
28. Oppenheim R.C. Solid colloidal drug delivery systems: nanoparticles. Int. J. Pharm. 1981, 8:217-234.
29. Owens D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307:93-102.
30. Roser M., Fischer D., Kissel T. Surface-modified biodegradable albumin nano- and microspheres. II. Effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur. J. Pharm. Biopharm. 1998, 46:255-263.
31. Schipper N.G.M., Olson S., Hoogstraate J.A., deBoer A.G., Varum K.M., Artursson P. Chitosan as absorption enhancers for poorly absorbable drugs. 2: Mechanism of absorption enhancement. Pharm. Res. 1997, 14:923-929.
32. Sosnik A., Chiappetta D.A., Carcaboso A.M. Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead. J. Control. Release 2009, 138:2-15.
33. Stolnik S., Dunn S.E., Garnett M.C., Davies M.C., Coombes A.G., Taylor D.C., Irving M.P., Purkiss S.C., Tadros T.F. Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm. Res. 1994, 11:1800-1808.
34. Stolnik S., Illum L., Davies S.S. Long circulating microparticulate drug carriers. Adv. Drug Deliv. Rev. 1995, 16:195-214.
35. Tobio M., Gref R., Sanchez A., Langer R., Alonso M.J. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm. Res. 1998, 15:270-275.
36. Ubrich N., Schmidt C., Bodmeier R., Hoffman M., Maincent P. Oral evaluation in rabbits of cyclosporine-loaded Eudragit RS or RL nanoparticles. Int. J. Pharm. 2005, 288:169-175.
37. Ugwoke M.I., Verbeke N., Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J. Pharm. Pharmacol. 2001, 53:3-21.
38. Vila A., Gill H., McCallion O., Alonso M.J. Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. J. Control. Release 2004, 98:232-244.
39. Vila A., Sanchez A., Calvo P., Tobyo M., Alonso M.J. Design of biodegradable particles for protein delivery. J. Control. Release 2002, 78:15-24.
40. Wang J., Tabata Y., Morimoto K. Aminated gelatin microspheres as a nasal delivery system for peptide drugs: evaluation of in vitro release and in vivo insulin absorption in rats. J. Control. Release 2006, 113:31-37.
41. Warnke D., Barreto J., Temesgen Z. Antiretroviral drugs. J. Clin. Pharmacol. 2007, 47:1570-1579.
42. Yarchoan R., Mitsuya H., Myers C.E., Broder S. Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N. Engl. J. Med. 1989, 321:726-738.
43. Zambaux M.F., Bonneaux F., Gref R., Maincent P., Dellacherie E., Alonso M.J., Labrude P., Vigneron C. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J. Control. Release 1998, 50:31-40.